Goldthread (Coptis spp.): A Comprehensive Reference
1. Identity and Botanical Classification
1.1 Genus and Principal Species
Goldthread (Coptis) is a genus of between 10 and 15 species of flowering plants in the family Ranunculaceae, native to Asia and North America. The term "goldthread" refers collectively to all species within this genus, but it is most consistently applied to three medicinally significant species:
- Coptis chinensis Franch. (Chinese goldthread; Huanglian or Weilian in Chinese) — the primary species in global commerce and research. It is a species of goldthread flowering plant native to China.
- Coptis teeta Wall. (Mishmi teeta) — a perennial herbaceous plant belonging to the Ranunculaceae family, rich in various bioactive compounds. It is classified as endangered on the Red List and is endemic to the Eastern Himalayas in Northeast India.
- Coptis trifolia (L.) Salisb. — commonly known as threeleaf goldthread or savoyane, a perennial plant in the family Ranunculaceae native to North America.
Additional species of regional medicinal significance include Coptis deltoidea C.Y.Cheng et Hsiao (Yalian), used in China, and Coptis anemonaefolia, used in Japan.
1.2 Taxonomic and Pharmacopoeial Name
The plant is a small member of the family Ranunculaceae with intensely yellow, branched rhizomes, feathery leaves, and small, five-petaled flowers. Based on the Chinese Pharmacopoeia Edition 2020, this species is one of the ingredients of a common botanical drug called Coptidis rhizoma (C. rhizoma, Chinese goldthread; Huanglian in Chinese). Coptidis rhizome (CR) is the rhizome of Coptis chinensis Franch., C. deltoidea C.Y. Cheng et Hsiao, or C. teeta Wall (Ranunculaceae).
1.3 Common Names and Synonyms
Chinese goldthread, ch'uan-lien, coptis rhizome, golden thread, and huang lian are all used to describe the dried rhizomes. Other names for the various species of coptis used in healing include goldthread, Chinese goldthread, mouth root, cankerroot, yellowroot, coptidis, mishmi bitter, and chonlin.
1.4 Botanical Description and Plant Part Used
Coptis is a low, creeping perennial evergreen that grows in damp boggy spots in woods. The plant produces a mass of thread-like golden rhizomes that are used in healing. C. chinensis is native to the cooler parts of Asia and is extensively cultivated in Szechwan province in China. The roots of the plant look like a tangled mass of gold thread, hence its name. Herbal goldthread is actually the powdered rhizome, or underground stem, of the goldthread plant.
For C. trifolia, it is a small perennial forb that spreads by slender, creeping rhizomes that are bright golden-yellow in color, hence the common name goldthread.
1.5 Common Preparations and Dosage Forms
CR has been employed in the form of powders, pills, or decoctions. In modern practice, preparations include standardized aqueous and alcoholic extracts of the dried rhizome, isolated berberine (the principal alkaloid), and proprietary multi-herb decoctions. In clinical settings, owing to affecting factors such as age, disease location, administration route, and processing method, CR exhibits a very wide daily single dose range of 1.5–40 g. For isolated berberine derived from Coptis, berberine is available as a food supplement, typically in capsule or tablet form, with study regimens often using divided doses of 500 mg to 1500 mg daily. The Memorial Sloan Kettering Cancer Center notes huanglian is used in traditional Chinese medicine for diarrhea, vomiting, abdominal fullness, jaundice, high fever, toothache, diabetes, and eczema.
2. Traditional and Historical Use
2.1 Traditional Chinese Medicine (TCM)
Since 3000 B.C., goldthread has been an integral part of Traditional Chinese Medicine (TCM) as Rhizoma coptidis. Coptis chinensis is one of the 50 fundamental herbs used in traditional Chinese medicine, where it is called duǎn è huánglián.
CR has been used to treat various inflammatory disorders and related diseases for a thousand years, and has functions of clearing heat, drying dampness, and detoxification according to traditional Chinese medicinal theory. The medicinal use of this plant was first listed in Shennong's Bencao Jing (the Divine Farmer's Classic of Materia Medica), one of the oldest Chinese pharmacopeias.
Relevant statistics show that in 13 prescriptions before the Song Dynasty, more than 32,000 Chinese medical formulae mentioned CR. In traditional Chinese medicine, coptis is used to treat conditions associated with excess dampness and excess heat, such as insomnia and irritability. "Heat" in TCM means excessive activity, not necessarily high temperature, although the diseased part of the body could be red or inflamed. Coptis is said to have a cold nature and a bitter taste.
It is associated with the heart, liver, stomach, and large intestine. More specifically, coptis is used to treat gastrointestinal problems such as diarrhea, vomiting, and bacterial dysentery. It is also used to treat chronic gallbladder inflammations. Other gastrointestinal conditions treated with coptis include abdominal cramps, acid reflux (heartburn), ineffective or painful bowel movements, and bloody stools.
Currently, CR is commonly used as a main traditional Chinese medicine to treat respiratory diseases (including tuberculous empyema, whooping cough, and pulmonary candidiasis caused by pneumonia), digestive diseases (including diarrhoea, chronic colitis, and upper gastrointestinal infection), paediatric diseases (including hyperthermia of infantile external sensation, dyspepsia, and urticaria), and dermatological diseases (including acne, psoriasis, dermatitis, and tinea pedis), and nervous system diseases.
In classic TCM books, Explanation of Materia Medica (Bencaojing Jizhu) and Tang Materia Medica (Tang Bencao) clarified that prescriptions containing Coptis chinensis can effectively alleviate the symptoms of polydipsia, polyphagia, and polyuria — conditions now recognized as diabetes mellitus.
A major classical formula, Huang-Lian-Jie-Du Decoction (HLJDD), which contains Coptis as a primary ingredient, was first prepared starting in the Tang dynasty and is still used today.
Coptis is considered effective as a hemostatic, which means that it can be used to stop bleeding. Chinese herbalists also use preparations made from coptis to relieve high fever and delirium. These preparations can be used as a gargle to relieve sore throats. Externally, coptis can be used as a mouthwash to treat all kinds of mouth sores, including canker sores, tongue ulcers, and swollen gums.
2.2 Ayurvedic and South Asian Use (Coptis teeta)
Various tribes in Arunachal Pradesh, India, have utilized C. teeta's potent therapeutic benefits for centuries to treat ailments such as gastrointestinal disorders, malaria, diabetes, eye disorders, and infectious diseases. Coptis teeta is used as a medicinal herb in China and the Eastern Himalayan regions of India, particularly in Mishmi Hills of Arunachal Pradesh, where it is used as a bitter tonic for treating malarial fever and dyspepsia. In India, the root of Coptis Teeta Wallich is much used as a bitter tonic by the natives, and is officinal in the Pharmacopoeia of India as "Coptidis Radix."
2.3 North American Indigenous and Traditional Use (Coptis trifolia)
The rhizome of C. trifolia was used by several Native American peoples, including many Algonquian peoples and the Haudenosaunee, to relieve canker sores and other ailments of the mouth — the source of the common name canker-root. It has also been used to make a tea used as an eyewash, as well as an anthelmintic, antiemetic, emetic, and gastrointestinal aid. Like the medicinal plant goldenseal, goldthread is used to treat symptoms of influenza and the common cold.
In French towns in Canada, it is known as Savoyanne, and it is sold in the French markets and extensively used in domestic medicine as a tonic and appetizer.
Also used in Japan, Coptis anemonaefolia is used in Japan in a manner analogous to the Chinese species.
3. Key Constituents and Active Compounds
3.1 Alkaloid Profile
Currently, 128 chemical constituents have been isolated and identified from CR. Alkaloids are the characteristic components, together with organic acids, coumarins, phenylpropanoids, and quinones.
To date, over 100 chemical constituents have been isolated and identified. Alkaloids are the most abundant among these chemical components and are considered the main active ingredients of CR. Besides alkaloids, CR contains organic acids, coumarins, phenylpropanoids, quinones, and other chemical components.
The principal alkaloids are isoquinoline derivatives of the protoberberine class. The active ingredients and the agents of the bitter taste of CR are mainly protoberberine-type alkaloids such as berberine, coptisine, jatrorrhizine, palmatine, columbamine, epiberberine, and magnoflorine.
Relative concentrations in the rhizome have been documented: berberine has the highest concentrations, followed by coptisine, palmatine, and epiberberine sequentially. More precisely, the major constituents are berberine and related protoberberine alkaloids; berberine occurs in the range of 4–8%, followed by palmatine, coptisine, and berberastine. One study of extracted fractions found the major component among the tested isoquinoline alkaloids was berberine (13) with a content of 6.21 ± 0.23%.
3.2 Berberine: The Principal Active Constituent
Berberine is a quaternary ammonium salt from the protoberberine group of isoquinoline alkaloids. It has a strong yellow color and in earlier days was used to dye wool, leather, and wood. Berberine is the most important active constituent and the primary toxic component of CR.
Genes involved in the biosynthesis of protoberberine-type alkaloids in C. chinensis have been characterized. Local genomic tandem duplications contribute to member amplification of a Ranunculales clade-specific gene family of the cytochrome P450 (CYP) 719. The functional versatility of a key CYP719 gene that encodes the (S)-canadine synthase enzyme involved in the berberine biosynthesis pathway may play critical roles in the diversification of berberine-related alkaloids in C. chinensis.
3.3 Coptisine
Coptisine is the second most abundant alkaloid and has attracted independent research interest. Berberine, the most abundant isoquinoline alkaloid in C. chinensis, has a history of treating bacteria-correlative diarrhoeas in the late 1900s. Coptisine itself shares structural similarity with berberine, and studies suggest it contributes to the plant's anti-inflammatory, antimicrobial, and anticancer properties, though coptisine is a promising compound with multiple targets; there is still a knowledge gap before coptisine meets the requirements to be introduced to clinical use.
Importantly, the alkaloids within CR interact with each other metabolically: there are different degrees of metabolic interaction between the four components; coptisine showed the strongest inhibition toward berberine metabolism.
4. Established Mechanisms of Action
4.1 Anti-inflammatory Pathways
Rhizoma coptidis and berberine strongly inhibit LPS-induced monocyte chemoattractant protein (MCP)-1 production in RAW cells. Activation of the transcription factors AP-1 and NF-κB is inhibited by Rhizoma coptidis in a dose- and time-dependent fashion. Rhizoma coptidis extract inhibits LPS-induced MCP-1/CCL2 production in vitro via an AP-1 and NF-κB–dependent pathway. Anti-inflammatory action of the extract is mediated mainly by its alkaloid compound berberine.
4.2 Antidiabetic Mechanisms
Berberine directly binds KCNH6 potassium channels, significantly accelerates channel closure, and subsequently reduces KCNH6 currents. This mechanism promotes insulin secretion from pancreatic β-cells. Additionally, berberine, a major alkaloid in Rhizoma Coptidis, reduces the protein expression of phosphoenolpyruvate carboxykinase and glucose-6-phosphatase in liver tissue, improves glucose tolerance, and decreases plasma hyperlipidemia.
The lipid-lowering effect of berberine appears to be mainly due to the stabilization of the hepatic LDL-C receptors (LDLR) by an extracellular signal-regulated kinase (ERK)-dependent pathway, and also by increasing transcriptional activity of the LDLR promoter by a c-Jun N-terminal kinase (JNK) pathway.
4.3 Antimicrobial Mechanisms
The extract significantly reduced ATPase and succinate dehydrogenase activities, decreased membrane potential, and disrupted cell wall and membrane integrity. These effects led to increased extracellular alkaline phosphatase activity and leakage of proteins and nucleic acids. Rhizoma coptidis is known to show anti-inflammatory and antiviral activity in addition to antimicrobial activity against Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Propionibacterium acnes, Streptococcus pneumoniae, Vibrio cholerae, Bacillus anthracis, and Bacillus dysenteriae, and antifungal activity against Candida albicans and Aspergillus niger.
4.4 Neuroprotective Mechanisms
The multifaceted molecular mechanisms responsible for berberine's neuroprotection encompass the attenuation of oxidative stress, mitigation of inflammatory responses, inhibition of apoptotic pathways, facilitation of autophagic processes, and modulation of CYP450 enzyme activities, neurotransmitter levels, and gut microbiota composition.
4.5 Anticancer Mechanisms
Anticancer mechanisms of Coptidis rhizoma and berberine are multifaceted, encompassing the inhibition of cancer cell proliferation, the prevention of metastasis, the induction of apoptosis, the facilitation of autophagy, the modulation of the tumor microenvironment and gut microbiota, and the enhancement of the efficacy of conventional therapeutic strategies.
5. Scientific Evidence by Area of Use
5.1 Diabetes and Glycemic Control
Traditional context: Berberine is the main active component of the ancient Chinese herb Coptis chinensis. For thousands of years, this herb has been used in traditional Chinese medicine to treat diabetes.
Clinical evidence: A pilot study was conducted to determine the efficacy and safety of berberine in the treatment of type 2 diabetic patients. In Study A, 36 adults with newly diagnosed type 2 diabetes were randomly assigned to treatment with berberine or metformin (0.5 g three times daily) in a 3-month trial. The hypoglycemic effect of berberine was similar to that of metformin. Significant decreases in hemoglobin A1c (HbA1c; from 9.5% ± 0.5% to 7.5% ± 0.4%), fasting blood glucose (FBG; from 10.6 ± 0.9 mmol/L to 6.9 ± 0.5 mmol/L), postprandial blood glucose (PBG; from 19.8 ± 1.7 to 11.1 ± 0.9 mmol/L), and plasma triglycerides were observed in the berberine group.
Clinical trials confirm that berberine monotherapy reduces glycated hemoglobin (HbA1c) by 1.5% in T2DM patients, comparable to metformin.
A systematic review and meta-analysis examined berberine's effect on metabolic profiles in type 2 diabetes, including intervention durations ranging from 4 weeks to 6 months; eleven trials compared berberine with placebo or none, while four trials compared berberine with metformin. Primary outcomes measured included glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG), and 2-hour postprandial blood glucose (2hPG).
A separate systematic review and meta-analysis examined C. chinensis-containing TCM as an adjunct to metformin, with primary outcomes including fasting blood glucose, 2-h postprandial blood glucose, glycosylated hemoglobin (HbA1c), fasting serum insulin, and homeostasis model assessment of insulin resistance (HOMA-IR).
Evidence strength: Multiple randomized controlled trials and meta-analyses support glucose-lowering effects of berberine in type 2 diabetes. The Memorial Sloan Kettering Cancer Center characterizes the human data as preliminary and notes that studies in humans are quite limited; preliminary data suggest huanglian and berberine may lower blood sugar levels, and well-designed clinical trials are needed. Most positive trials are of short duration, conducted largely in Chinese populations, and many use berberine as an isolated compound rather than the crude herb.
5.2 Cardiovascular Health and Lipid Metabolism
Berberine has been routinely used to treat diarrhea in many Asian countries. In recent decades, berberine has been proven to have anti-hyperlipidemia, anti-inflammatory, anti-atherosclerotic, neuroprotection, and vasculoprotective properties in the cardiovascular system, and is widely used in CVDs such as dyslipidemia, atherosclerosis, hypertension, heart failure, ischemia-reperfusion heart damage, coronary heart disease, stroke, and arrhythmias.
Clinical evidence: In a comprehensive systematic review and meta-analysis of 27 randomized controlled trials, berberine effectively reduced low density lipoprotein cholesterol (LDL-c) (−0.65 mmol/L, 95% CI −0.75 to −0.56), triglycerides (TG) (−0.39 mmol/L, 95% CI −0.59 to −0.19), total cholesterol (TC) (−0.66 mmol/L, 95% CI −1.02 to −0.31), and increased high density lipoprotein cholesterol (HDL-c) (0.07 mmol/L, 95% CI 0.04 to 0.1).
A randomized, double-blind, placebo-controlled, parallel trial enrolled 84 eligible Chinese men with hyperlipidemia who were randomized to berberine (500 mg orally, twice a day) or placebo for 12 weeks, assessing CVD risk factors including lipids, thromboxane A2, blood pressure, body mass index, and waist–hip ratio. Results showed that 80 men completed the trial; men randomized to berberine had larger reductions in total cholesterol (−0.39 mmol/L, 95% confidence interval −0.70 to −0.08) after 12 weeks.
In improving blood lipids, berberine alone had no significant effect on certain composite endpoints, but berberine combined with statins showed greater benefits on TC, TG, and LDL-C for patients with atherosclerosis, coronary heart disease, or ischemic stroke.
Evidence strength: Evidence from RCTs and meta-analyses for lipid lowering is moderately strong, though most trials are short-term and conducted primarily in East Asian populations. Effects on hard cardiovascular endpoints (mortality, myocardial infarction) have not been robustly demonstrated in human trials.
5.3 Antimicrobial and Gastrointestinal Infections
CR has been widely used to treat bacillary dysentery, diabetes, pertussis, sore throat, aphtha, and eczema in China. Berberine has demonstrated laboratory activity against a broad range of pathogens: berberine has demonstrated bacteriostatic effects against Streptococcus hemolyticus and Staphylococcus aureus.
Coptis trifolia has been shown to be biologically active against E. coli and Bacillus subtilis. The active compounds of C. trifolia are the alkaloids berberine and coptine.
Evidence strength: Antimicrobial evidence is predominantly in vitro (cell culture and animal studies). Lab studies suggest that berberine, a compound in huanglian, stops the growth of bacteria; however, human data are lacking. Similarly, lab studies support its use for diarrhea and other GI symptoms, but clinical data are lacking. Some historical use of berberine in treating bacterial diarrhea in clinical settings in Asia has been documented, but rigorous placebo-controlled human trials are limited.
5.4 Anti-inflammatory and Dermatological Applications
The Chinese medicine Rhizoma coptidis is well established in the treatment of common dermatological disorders, although the mechanism of its anti-inflammatory effects has previously remained elusive. Researchers stimulated an inflammatory state in human keratinocyte cultures using TNF-α in the presence of Rhizoma coptidis extract and berberine, to identify the dose-dependent anti-inflammatory role of these compounds. The conclusion was that in dermatological disorders, berberine exerts its anti-inflammatory effects by inhibiting signal transduction pathways other than the NF-κB–dependent pathway, while the Rhizoma coptidis complex acts partially by blocking the NF-κB-dependent pathway.
Evidence strength: Evidence for dermatological use is primarily from in vitro studies and animal models. Human clinical trials for specific skin conditions are sparse and limited in scope.
5.5 Neuroprotection and Central Nervous System
Berberine possesses various bioactivities, including antioxidant, anti-inflammation, anticancer, immune-regulation, and antimicrobial activities. Growing scientific evidence underscores berberine's substantial neuroprotective potential, prompting increased interest and scrutiny.
Accumulated evidence from clinical trials underscores the wide-ranging therapeutic applications of berberine. Among randomized clinical trials involving berberine and barberry in the treatment of different human diseases, the effects of reducing lipids and improving insulin resistance are the most studied. Additionally, clinical investigations have delved into its potential benefits in cardiovascular, anticancer, gastrointestinal, central nervous system, and endocrine-related contexts.
Evidence strength: Neuroprotective effects of berberine from Coptis are established primarily in preclinical (cell culture and animal) models. Human clinical evidence specific to neurological conditions remains preliminary and insufficient to support therapeutic claims.
5.6 Anticancer Properties
Berberine is a main component of Rhizoma Coptidis. Modern medicine has confirmed that berberine has pharmacological activities, such as anti-inflammatory, analgesic, antimicrobial, hypolipidemic, and blood pressure-lowering effects. Importantly, the active ingredient of berberine has clear inhibitory effects on various cancers, including colorectal cancer, lung cancer, ovarian cancer, prostate cancer, liver cancer, and cervical cancer.
Chemotherapy drugs combined with natural compounds like berberine have shown promising results in treating cancer. For example, rapamycin and berberine were combined to improve hepatocellular carcinoma therapy by restraining the mTOR signaling pathway.
Evidence strength: Anti-cancer evidence for Coptis and berberine is predominantly preclinical (in vitro cell lines and animal models). There is a lack of robust human clinical trial data confirming therapeutic efficacy in oncology settings. Research is active and ongoing.
5.7 Insulin Secretion Mechanism (Recent Findings)
Berberine significantly increases insulin secretion and reduces blood glucose levels in mice with hyperglycemia induced by a high-fat diet. However, in mice with hyperglycemia induced by pancreatic islet β-cell-specific Kcnh6 knockout, berberine does not exert beneficial effects. Berberine directly binds KCNH6 potassium channels, significantly accelerates channel closure, and subsequently reduces KCNH6 currents. A phase 1 clinical trial in humans was conducted to assess this mechanism (NCT03972), though detailed published results remain pending from the referenced source.
6. Body Systems and Health Areas
Various pharmacological properties of the alkaloids from C. chinensis have been reported, including properties for treating generally infective and inflammatory diseases, as well as properties related to the prevention and treatment of health problems related to cardiovascular, diabetes, cancer, and the nervous system.
- Gastrointestinal system: Treatment of diarrhea, dysentery, gastritis, chronic colitis, upper GI infection, abdominal cramps, vomiting.
- Metabolic/endocrine system: Blood glucose regulation, lipid lowering, insulin sensitization, metabolic syndrome.
- Cardiovascular system: Lipid management, anti-atherosclerotic effects, antiarrhythmic, antihypertensive properties.
- Immune and infectious disease: Broad-spectrum antimicrobial, antiviral, antifungal activities.
- Dermatological system: Acne, psoriasis, dermatitis, tinea pedis, wound healing, eczema.
- Nervous system: Neuroprotection, modulation of neurotransmitter systems, potential in mood and cognitive disorders (primarily preclinical).
- Oncological: Preclinical anticancer activity across multiple cancer types.
Accumulating studies have reported a broad spectrum of pharmacological benefits of Coptidis rhizoma such as antiviral, antibacterial, antifungal, effects in hepatic steatosis, antiatherosclerotic, antiarrhythmic, antihypertensive, cardioprotective, antidiabetic, anti-inflammatory, antioxidative, neuroprotective, and anticancer activities.
7. Dosage Forms and Reported Study Dosages
Crude herb (Coptidis rhizoma): In clinical settings, depending on factors such as age, disease location, administration route, and processing method, CR exhibits a very wide daily single dose range of 1.5–40 g.
Isolated berberine — diabetes studies: In a randomized trial, 36 adults with newly diagnosed type 2 diabetes were assigned to berberine or metformin (0.5 g three times daily).
Isolated berberine — cardiovascular study: 84 eligible Chinese men with hyperlipidemia were randomized to berberine (500 mg orally, twice a day) or placebo for 12 weeks.
Supplement market context: Berberine is available as a food supplement, typically in capsule or tablet form; study regimens often use divided doses of 500 mg to 1500 mg daily for limited durations.
Animal study dosing (for reference only): In rats, pretreatment with different doses of berberine (30 or 120 mg/kg body weight) or C. chinensis aqueous extract (containing 9.9% berberine; 300 mg/kg body weight) was used in experimental sepsis models.
8. Safety Considerations and Drug Interactions
8.1 Acute Toxicity
The oral LD50 of isolated berberine from Rhizoma coptidis is 713.58 mg/kg in mice, which is classified in the slight toxicity rank. The comparison of the fibrous root of Rhizoma coptidis (FRC) with Rhizoma coptidis (RC) revealed LD50 values of FRC and RC were greater than 7 and 4.89 g/kg in mice, respectively. The content of berberine in FRC and RC measured by HPLC was 1.20 and 5.61%, respectively. The lower toxicity effects of FRC can be attributed to the lower content of its berberine.
8.2 Berberine as Primary Toxic Component
Berberine is not only the main active component but also the primary toxic component of CR. Consequently, it is crucial to develop a strategy to balance the pharmacological effects and toxicity of berberine.
8.3 Neonatal Jaundice and Pediatric Contraindication
Huanglian displaces bilirubin and should not be administered to jaundiced neonates. The incidence of kernicterus in premature Chinese infants with neonatal jaundice and glucose-6-phosphate dehydrogenase (G6PD) deficiency has, in some cases, been reported to be associated with exposure to Coptis, either by direct administration, transplacental absorption, or via breast milk (berberine can be transferred to the infant via breastfeeding).
Theoretically, Coptis may increase bilirubin levels in laboratory tests due to its berberine content. Berberine may cause an increase in total and unbound bilirubin concentrations as it has been shown to displace bilirubin from albumin in preliminary studies.
8.4 Pregnancy and Lactation
Berberine may worsen jaundice in infants or cause a more severe condition that can lead to brain disorders, and should be avoided during pregnancy or breastfeeding. Human safety data for berberine in pregnancy are insufficient. Case reports and animal data suggest potential harm, and some reports link exposure to neonatal jaundice. Because fetal and neonatal physiology is unique and vulnerable, most clinicians recommend avoiding berberine during pregnancy unless under strict specialist oversight.
8.5 Cardiac Effects
Berberine-containing botanicals may prolong QTc in patients with underlying heart disease. This potential cardiac effect requires particular attention in individuals with pre-existing arrhythmias or those taking medications that also affect cardiac conduction.
8.6 CYP450 Enzyme Interactions
Huanglian/CYP450 substrates: Huanglian inhibits CYP2D6, CYP2C9, and CYP3A4, and may affect drugs metabolized by these enzymes. Prolonged use of huanglian can also induce 3A4 by activating pregnane X receptor. Clinical significance is not known.
The mechanism for the CYP3A4 interaction may be due to the inhibition of cytochrome P450 3A4 (CYP3A4) by berberine in the liver and/or small intestine. Due to preliminary evidence showing that berberine potentially inhibits CYP450 enzymes, Coptis may theoretically increase the level of drugs metabolized by these enzymes.
A human pharmacokinetic study specifically confirmed this: berberine is a major isoquinoline alkaloid in herbs such as goldenseal, berberis, and Coptis chinensis, and repeated administration has been shown to inhibit cytochromes P450 in humans.
8.7 Cyclosporine and Immunosuppressant Interaction
Due to its berberine content, Coptis may reduce the metabolism of cyclosporine (an immunosuppressant drug) and increase serum levels. This combination may allow a reduction of cyclosporine dosage under appropriate supervision.
8.8 Interaction with Diabetes Medications and Anticoagulants
Significant drug interactions occur via CYP450 enzymes and P-glycoprotein, particularly with diabetes medications, anticoagulants, and statins. Berberine is contraindicated in pregnancy, breastfeeding, and neonates; it requires caution in liver or kidney disease and should be stopped before surgery.
8.9 Intra-constituent Metabolic Interactions
The study investigated metabolic interactions of the active constituents (berberine, coptisine, palmatine, and jatrorrhizine) of Coptis chinensis in human liver microsomes. After incubation of the four constituents in human liver microsomes (HLMs), the metabolism of the four constituents was observed by HPLC, and in vitro inhibition experiments were conducted. There are different degrees of metabolic interaction between the four components; coptisine showed the strongest inhibition toward berberine metabolism. This intra-herb metabolic interplay means that whole-herb preparations may produce different pharmacokinetic profiles than isolated berberine supplements.
8.10 Bioavailability Limitations
Some studies suggested that the availability of berberine appeared extremely low after oral administration of berberine in humans and rats. This poor oral bioavailability has prompted pharmaceutical research into nano-delivery systems and other formulation strategies to enhance absorption, though these remain largely experimental.
8.11 Bitter Nature and Gastrointestinal Tolerability
The bitter and cold nature of CR can irritate the spleen and stomach, and certain ingredients in CR may trigger allergic reactions. Herb combinations can help alleviate the side effects caused by CR.
8.12 Conservation Status
The conservation status of certain Coptis species is an important practical consideration for sourcing. Studies have shown that Coptis teeta has become endangered both due to overexploitation as well as intrinsic genetic bottlenecks such as high cytoplasmic male sterility induced by genetic mutations.
References
Go back